In summary, FLT3L combined with GM-CSF induced DCs, through their unique subpopulation composition and functional state, can more effectively expand tumor-specific CD8+ T cells and reshape the tumor microenvironment, thereby achieving superior immunotherapy outcomes. This evidence concerns the gene CSF2 and neoplasm.